Safety and Efficacy of Triamcinolone 0.1% in Infants

Introduction to Safety Concerns

• The hypothalamic-pituitary-adrenal (HPA) axis suppression is a key safety concern when using triamcinolone 0.1%, which is dependent on the potency of the corticosteroid, application site, duration of use, and body surface area covered 1

Appropriate Clinical Use Guidelines

• The American Academy of Pediatrics recommends avoiding triamcinolone 0.1% on high-absorption areas such as the face, diaper area, and intertriginous regions where adverse effects are more likely 2

Monitoring and Contraindications

• Parents should be instructed to watch for Cushingoid features (moon facies, weight gain) indicating systemic absorption, and local skin changes including atrophy, telangiectasias, or striae 2
• Growth concerns, though transient growth suppression is more commonly associated with intranasal or inhaled corticosteroids rather than limited topical use, should be monitored 1, 4
• The American Academy of Pediatrics recommends avoiding triamcinolone 0.1% in infants with active skin infection, as corticosteroids can worsen infection 2